Intervacc AB

Intervacc AB operates with a capital structure that is predominantly equity-funded, as evidenced by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company's liquidity position is characterized by a current ratio of 4.88, suggesting strong short-term liquidity. However, the company's operating cash flow is negative at -16,312,000 SEK, and free cash flow is also negative at -12,864,000 SEK, indicating ongoing cash outflows from operations. Profitability metrics for Intervacc are negative, with a return on equity of -7.88% and a return on assets of -7.28%, both significantly below the industry median for biotechnology firms. The company reported a net loss of 17,389,000 SEK and an operating loss of 17,979,000 SEK, reflecting the high costs associated with vaccine development and commercialization. Geographically, Intervacc's revenue is concentrated in a limited number of markets, with no disclosed segment or geographic breakdown in the provided data. This lack of diversification could expose the company to regional economic or regulatory risks. The company's revenue for the latest period was 23,940,000 SEK, with a gross profit of 4,110,000 SEK, indicating a gross margin of approximately 17.16%. Looking ahead, Intervacc's growth trajectory is uncertain, as the company is currently reporting losses and has not provided a clear path to profitability. Analysts have estimated a mean revenue of 44,300,000 SEK for the next period, which would represent a 96.1% increase from the latest reported revenue of 22,284,000 SEK. However, the company's net loss and negative cash flows suggest that achieving this growth may be challenging without significant operational improvements or external financing. The company's risk profile is moderate, with a liquidity risk rating of medium and a dilution risk rating of low. The key risk flag is the negative net cash position after subtracting total debt, which could limit the company's ability to fund operations without additional capital. The company has not issued any new shares recently, and there is no indication of dilution pressure in the near term. Recent events and disclosures indicate that Intervacc is focused on vaccine development and commercialization, with no major regulatory or legal issues reported. The company's financial performance has been volatile, with a net loss in the latest period and a significant decline in revenue compared to previous periods. Analysts have set a mean price target of 2.20 SEK, which is unchanged from the median, high, and low price targets, suggesting a lack of consensus on the company's future performance.